Sofinnova Partners — 2020 Investments
7 investments dated 2020 · listed companies and verified rows first · show all
Genespire is a life sciences company backed by multiple venture capital investors including Sofinnova Partners, XGEN Venture, CDP Venture Capital, and Indaco Venture Partners.
BiotechDeep TechDigital HealthHealthtech
Dr. Lucia Faccio(Chief Executive Officer)inDr. Julianne Smith(Chief Development Officer)Dr. Simon Hawkins(VP Clinical Development)Dr. Smaragda Angelidou(Responsabile CMC)Dr. Mary Wang(Patient Engagement Director)Emanuela Balzo(VP of Finance)in
Co-investorsCDP Venture CapitalIndaco Venture PartnersXGEN Venture
Catamaran Bio develops allogeneic CAR-NK cell therapies for cancer treatment, focusing on solid tumors, by combining natural killer (NK) cell biology with synthetic biology and non-viral cell engineering.
BiotechHealthtech
Branden Moriarity(Scientific Co-founder)Catherine Bollard(Scientific Co-founder)
Co-investorsAstellas Venture Management LLCLightstone Ventures
Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment.
BiotechMedical DevicesLondon, GB
Co-investorsBrandon Capital PartnersNovo HoldingsAbingworth
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.
BiotechHealthtechLongevity
Irene Griswold-Prenner(Founder & Chief Executive Officer)in
Co-investorsMission BiocapitalAbbVieDementia Discovery FundMission Bay Capital
Pi-Cardia develops non-implant-based, catheter-delivered devices for treating structural heart disease, including its ShortCut product for leaflet modification.
HardwareHealthtechMedical Devices
Erez Golan(Founder)in
Co-investorsAccelmed PartnersClal Biotechnology IndustriesIndaco Venture Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Gradient Denervation TechnologiesPyrowave
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.